- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Allergan markets combo solution in Europe
Irvine, CA-The European Commission granted Allergan a license to market its bimatoprost/timolol ophthalmic solution (Ganfort) in the European Union.
Irvine, CA-The European Commission granted Allergan a license to market its bimatoprost/timolol ophthalmic solution (Ganfort) in the European Union. The once-daily combination product is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension who have insufficient response to topical beta-blockers or prostaglandin analogues.
The bimatoprost/timolol ophthalmic solution offers powerful IOP-lowering efficacy comparable to the free combination of these two agents, and greater efficacy than monotherapy with either agent used alone, according to Allergan.
The company added that the combination treatment had a superior tolerability profile, including 40% less hyperemia compared with bimatoprost monotherapy.
